OP35: Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 studyECCO'24 Stockholm 2024
OP36: Risankizumab Versus Ustekinumab for the Achievement of Clinical Outcomes and Symptom Improvement in Patients With Moderate To Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE TrialECCO'24 Stockholm 2024
OP37: Effect of the HLA-DQA1*05 allele on the efficacy of ustekinumab in patients with Crohn's Disease. Multicenter study based on the ENEIDA registry of GETECCU.ECCO'24 Stockholm 2024
OP38: Should all patients with newly diagnosed inflammatory bowel diseases be screened for metabolic bone disease? Results from a Danish population-based inception cohort studyECCO'24 Stockholm 2024
OP39: Vedolizumab response in ulcerative colitis associates with reduced IgG+ plasma cells and FcγR signalingECCO'24 Stockholm 2024
OP40: Transcriptomic signature of response to vedolizumab in patients with moderate-to-severe ulcerative colitis: Results from an international, multicentre, retrospective cohort studyECCO'24 Stockholm 2024
SCI08: Charting Frontiers: European Insights into Global Trends in IBD EpidemiologyECCO'24 Stockholm 2024